Aurora A Kinase Allosteric Monobody Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule kinase inhibitors targeting the ATP binding site of Aurora A kinase are not specific, leading to side effects and a need for more targeted methods to modulate kinase activity in cancer treatment.
Innovation Solution
Development of antibody mimetics, specifically monobodies, that bind to the allosteric PIF pocket of Aurora A kinase, disrupting TPX2 binding and modulating kinase activity to inhibit cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule kinase inhibitors are developed to target the ATP binding site of Aurora A kinase, then kinase activity can be inhibited, but the drugs are not specific for the particular kinase leading to side effects
Solution Approach 1:
The patent applies local quality by targeting a specific allosteric site (PIF pocket) on Aurora A kinase rather than the conserved ATP binding site. This localized targeting approach allows the antibody mimetic to selectively bind to Aurora A's unique structural features, achieving kinase inhibition while avoiding off-target effects on other kinases that share the ATP binding site.
Solution Approach 2:
The patent uses an antibody mimetic as an intermediary molecule that bridges the gap between the desired specificity and the target kinase. This intermediary agent binds to the allosteric PIF pocket, indirectly modulating kinase activity without directly competing for the ATP binding site, thereby achieving both efficacy and specificity.
2Object-affected harmful factors
If antibody mimetics are developed to target the allosteric PIF pocket of Aurora A kinase, then specificity is improved, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent extracts only the essential antigen-binding functionality from full antibodies, using minimal antibody fragments (such as scFv or Fab fragments) that retain the ability to specifically bind the PIF pocket. This extraction approach maintains the specificity benefits of antibody-based targeting while reducing the molecular complexity and size of the therapeutic agent.
Solution Approach 2:
The patent segments the antibody structure into functional domains, utilizing only the variable regions (VH and VL) that are responsible for antigen binding. This segmentation allows the creation of simplified antibody mimetics that preserve target specificity while eliminating unnecessary structural complexity associated with full-length antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody mimetics demonstrate high specificity and affinity for Aurora A kinase, effectively inhibiting or activating kinase activity, thereby reducing cancer cell survival and proliferation with reduced side effects.
Implementation Method 1
an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase
Data Source
AI summary
The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.